FAPI-PET for Tumor Detection

Status Recruiting

Clinical Trial Summary

This is a prospective observational trial investigating correlation with histopathology, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or PET/MRI in patients receiving this imaging modality for tumor staging or restaging as part of clinical care.

Clinical Trial Description

68-Ga-fibroblast-activation-protein-inhibitors (68-Ga-FAPI) are novel Positron emission tomography (PET) tracers that were recently introduced for the imaging of patients with various cancer diseases. The fibroblast-activation-protein (FAP) is highly expressed in carcinoma-associated fibroblasts (CAFs) in the stroma of various tumor entities. The aim of this registry study is to collect data on FAPI expression, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or PET/MRI on patients receiving this imaging modality at initial diagnosis or restaging as part of clinical care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04571086
Study type	Observational [Patient Registry]
Source	University Hospital, Essen
Contact	Wolfgang Fendler, MD
Phone	+49 201 723 1862
Email	wolfgang.fendler@uk-essen.de
Status	Recruiting
Phase
Start date	April 30, 2020
Completion date	April 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Active, not recruiting	`NCT02243592` - Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Completed	`NCT03445572` - Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer	N/A
Active, not recruiting	`NCT02860039` - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant	Phase 2
Completed	`NCT01946217` - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials	N/A
Completed	`NCT01635413` - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)	N/A
Completed	`NCT00026169` - Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure	Phase 1
Recruiting	`NCT04534075` - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial	Phase 3
Active, not recruiting	`NCT01806129` - Reproductive Health Program in Patients With Cancer	N/A
Recruiting	`NCT03915717` - Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Recruiting	`NCT02280161` - Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
Recruiting	`NCT05520281` - Short-term Psychodynamic Psychotherapy in Serious Physical Illness	N/A
Terminated	`NCT00532064` - Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
Completed	`NCT04990882` - FAPI PET/CT Prospective Interobserver Agreement
Completed	`NCT01896778` - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer	N/A
Recruiting	`NCT05770102` - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Phase 2/Phase 3
Recruiting	`NCT06090266` - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Recruiting	`NCT05886764` - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials	N/A
Completed	`NCT01432431` - Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff	N/A
Completed	`NCT01506440` - Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy